EGFR E746_T751delinsA

CI-VAR-00000842Explore in graph →NP_005219.2:p.Glu746_Thr751delinsAlaNM_005228.3:c.2237_2251delClinVar 177645 CIViC 1004 rs121913425

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR E746_T751delinsA	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4222 In a lung adenocarcinoma patient with EGFR E746_T751>A mutation EGFR E746_A751>A was associated with improved response to erlotinib treatment. The patient was treated with erlotinib monotherapy and ac… (full text at CIViC) PMID 17085664 · Balak et al., 2006 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma4
EGFR E746_T751delinsA	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4221 A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC) PMID 19671843 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.